Mme BOUARD Adeline

Fiche personne

Coordonnées

EFS Bourgogne Franche-Comté
8 rue du Docteur Jean-François-Xavier Girod
BP 1937

25020 BESANCON Cedex

Territoire

Franche-Comté

Statut

Ingénieur/Technicien

Affiliation

Etablissement Français du Sang Bourgogne-Franche-Comté (EFS Bourgogne - Franche-Comté)

Équipes/plateformes

ITAC

Publications

Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery.

Abdeljaoued S, Doussot A, Kroemer M, Laloy E, Pallandre JR, El Kaddissi A, Spehner L, Ben Khelil M, Bouard A, Mougey V, Chartral U, Vienot A, Viot J, Lakkis Z, Monnien F, Loyon R, Borg C

Oncoimmunology. 2025 12;14(1):2455176

Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

El Kaddissi A, Vienot A, Fumet JD, Meurisse A, Nguyen T, Klajer E, Bouard A, Spehner L, Fein F, Stouvenot M, Dochy E, Rebucci-Peixoto M, Almotlak H, Henriquez J, Selmani Z, Vernerey D, Hervouet E, Folletet A, Kim S, Ghiringhelli F, Borg C

ESMO Gastrointest Oncol. 2025 12;10:100270

Targeting SALL4 with an HLA Class I-restricted TCR for cancer immunotherapy.

Ben Khelil M, Fredon M, Adib N, Bouard A, Perchaud M, Abdeljaoued S, Mantion CF, Asgarov K, Guillaume P, Spehner L, Seffar E, Labesse M, Vienot A, Mougey V, Gonçalves-Venturelli M, Bobisse S, Harari A, Jandus C, Garnache-Ottou F, Binda D, Adotévi O, Godet Y, Kroemer M, Borg C, Loyon R

Cancer Immunol Res. 2025 10 20;:

Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.

Spehner L, Bouard A, El Kaddissi A, Kroemer M, Kim S, Nguyen T, Klajer E, Fein F, Abdeljaoued S, Loyon R, Borg C, Vienot A

Int J Cancer. 2025 08 16;:

AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies.

Musnier A, Corde Y, Verdier A, Cortes M, Pallandre JR, Dumet C, Bouard A, Keskes A, Omahdi Z, Puard V, Poupon A, Bourquard T

Front Immunol. 2025 03 11;16:1499810

Stanniocalcin 1 in patients with refractory colorectal cancer treated with regorafenib: A post-hoc biomarker analysis of the TEXCAN and CORRECT trials.

Vienot A, Vernerey D, Bouard A, Klajer E, Kim S, Tournigand C, Louvet C, Andre T, Rousseau B, Wespiser M, Spehner L, Wang YA, Weispfenning A, Dochy E, Borg C

Cancer Res Commun. 2025 01 14;:

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H, Kim S, Curtit E, Meynard G, Jary M, Nardin C, Asgarov K, Abdeljaoued S, Chartral U, Mougey V, Ben Khelil M, Lopez M, Loyon R, Vernerey D, Adotevi O, Borg C, Mansi L, Kroemer M

BMJ Oncol. 2023 12 14;2(1):e000054

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

Orillard E, Spehner L, Mansi L, Bouard A, Falcoz A, Lepiller Q, Renaude E, Pallandre JR, Vienot A, Kroemer M, Borg C

Front Immunol. 2023 06 2;14:1160664

CD8 CD226 T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.

Viot J, Abdeljaoued S, Vienot A, Seffar E, Spehner L, Bouard A, Asgarov K, Pallandre JR, Renaude E, Klajer E, Molimard C, Monnien F, Bibeau F, Turco C, Heyd B, Peixoto P, Hervouet E, Loyon R, Doussot A, Borg C, Kroemer M

Cell Mol Immunol. 2023 01 30;:

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

Vienot A, Monnien F, Truntzer C, Mougey V, Bouard A, Pallandre JR, Molimard C, Loyon R, Asgarov K, Averous G, Ghiringhelli F, Bibeau F, Peixoto P, Borg C

Mol Oncol. 2023 01 1;:

Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.

Vienot A, Pallandre JR, Renaude E, Viot J, Bouard A, Spehner L, Kroemer M, Abdeljaoued S, van der Woning B, de Haard H, Loyon R, Hervouet E, Peixoto P, Borg C

Oncoimmunology. 2022 11 12;11(1):2144669

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, Vernerey D, Meurisse A, Kim S, Borg C, Mansi L

Front Oncol. 2022 07 19;12:957580

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M

Eur J Cancer. 2021 Mar 26;150:1-9

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases.

Kroemer M, Turco C, Spehner L, Viot J, Idirène I, Bouard A, Renaude E, Deschamps M, Godet Y, Adotévi O, Limat S, Heyd B, Jary M, Loyon R, Borg C

J Immunother Cancer. 2020 Nov;8(2):

Fiche personne Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques